JMAR Retains Agile Equity to Identify BioSentry Partners
The system has completed successful testing with Princess Cruises, part of Carnival Corporation, one of the largest vacation companies in the world, and with the City of Anaheim, one of California's most populous tourist areas. Earlier this year, JMAR successfully completed water quality tests for Kimpen, S.A. de C.V., Mexico's leading beverage development and manufacturing company. In addition, the Company sold two BioSentry systems to the City of Wichita for drinking water quality and security monitoring in its municipal water plant.
Dr. Neil Beer, JMAR's president and CEO, said: "We are pleased to report activity in a multitude of markets. In addition to the cruise ship industry and homeland security, BioSentry has attracted customers in industry segments such as beverage manufacturing, the pharmaceutical and semiconductor industries, hospital and vision care, among others. This real-time pathogen detection system is ready for the right partner to accelerate sales growth."
About Agile Equity
Founded in 1996, Agile Equity is an investment bank specializing in the technology sector. Located on Park Avenue in New York City, Agile Equity is led by a strong team of corporate finance professionals with extensive transaction experience providing strategic and financial advice to leading companies worldwide. For additional information, please contact Ben Boissevain, Managing Partner at Agile Equity, at 212-475-1100, or by e-mail email@example.com.
JMAR Technologies, Inc. is a leading innovator in the development of laser-based technology for imaging, analysis and fabrication at the nanoscale. The Company is leveraging more than a decade of laser and photonics research to develop a diverse portfolio of products with commercial applications in rapidly growing industries, while continuing to carry out research and development for the U.S. Government. JMAR is targeting the nanotechnology, bioscience and semiconductor industries with its BriteLight(TM) Laser; X-ray Light Source; Compact X-ray Microscope -- for 3D visualization of single cells and polymers; and the X-ray Nano Probe -- enabling interaction, analysis and materials modification at the nanoscale. JMAR maintains a strategic alliance with FemtoTrace, a unique company applying NASA technology to trace analytical solutions, for the production of the READ chemical sensor for the homeland security, environmental and utility infrastructure industries. JMAR develops, manufactures and markets its BioSentry(TM) microorganism early-warning system for cruise ships, municipalities, pharmaceutical and semiconductor industries.
This news release contains certain "forward-looking statements." Forward-looking statements are based on current expectations and assumptions and are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, and many of which are beyond the Company's control. Actual results could differ materially from these forward-looking statements as a result of a number of factors, including the risk that the performance validation tests of the BioSentry Beta units are not successfully completed due to unforeseen issues with the installation and operation of the units outside of the controlled environment of JMAR's facility, delays in completion of the X-ray Microscope and X-ray Nano Probe prototypes and transition to production units, the failure of the technology to perform as predicted, competition from alternative technologies, uncertainties as to the size of the markets, cost and margins for JMAR's products, failure to obtain market acceptance, current or future government regulations affecting the use of JMAR's products, the lack of availability of critical components, the degree of protection from future patents, other risks associated with the development or acquisition of new products or technologies and those risks detailed in the Company's Form 10-K for the year ended December 31, 2005 filed with the SEC. Given these risks and uncertainties, investors are cautioned not to place undue reliance on such forward-looking statements and no assurances can be given that such statements will be achieved. JMAR Technologies, Inc. does not assume any duty to publicly update or revise the material contained herein.